Eli Lilly and Company $LLY Shares Acquired by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 1,083.8% during the third quarter, Holdings Channel reports. The institutional investor owned 3,954 shares of the company’s stock after acquiring an additional 3,620 shares during the quarter. Eli Lilly and Company makes up approximately 0.9% of Brown Miller Wealth Management LLC’s investment portfolio, making the stock its 28th largest position. Brown Miller Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,017,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. boosted its stake in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc increased its stake in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LLY shares. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a research report on Thursday, December 4th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a report on Monday, December 1st. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. Finally, Wolfe Research increased their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Five analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Buy” and an average target price of $1,155.36.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,079.83 on Friday. The stock’s fifty day moving average is $1,013.16 and its two-hundred day moving average is $850.82. The firm has a market capitalization of $1.02 trillion, a P/E ratio of 52.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks upgraded LLY from Hold to Strong Buy, a near-term catalyst that can attract buying from model-driven and income-focused investors. Zacks Research upgrade
• Positive Sentiment: Articles pushing a potential “surprise dividend” narrative have resurfaced, boosting investor interest in Lilly as a must-own 2026 idea if management signals shareholder returns. Eli Lilly’s surprise dividend story could be a 2026 must-own
• Positive Sentiment: Investor write-ups (e.g., InsiderMonkey) reiterate Lilly’s strong fundamentals and leadership in GLP-1s, supporting the case for LLY as a core holding. Positive third‑party commentary can sustain buying. What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
• Positive Sentiment: MarketBeat flagged Lilly’s progress advancing two additional weight‑loss drugs (one nearing approval) — successful trial/approval news would be a major upside catalyst for revenue growth. Eli Lilly’s new drug data sets up a high‑stakes 2026
• Neutral Sentiment: Broader market strength at the start of 2026 lifted many large caps, including LLY; macro momentum (vs. company-specific news) is supporting the move. MarketBeat Week in Review – 12/29 – 01/02
• Neutral Sentiment: Coverage noting price cuts for GLP‑1 drugs in China (Novo and reports of LLY pricing moves) highlights regional pricing pressure — this could temper upside but impact is currently uncertain and depends on scale. Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
• Negative Sentiment: Two recent commercials have drawn viewer backlash and accusations over messaging; while not yet a material business issue, negative publicity can affect brand perception and invite scrutiny. Company Facing Backlash For ‘Ridiculous’ Rose Bowl Commercial
• Negative Sentiment: Another piece highlights viewer division over an alleged “pro‑obesity” message in a new ad — reputational noise that could weigh on sentiment if amplified. New Eli Lilly commercial divides viewers

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.